Healthcare
Live Price
Offline$3.17
-7.31% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cytocom, Inc. (CBLI) is a Healthcare stock with a market cap of $226.39M. The stock last traded around $3.17. Baseline metrics include revenue growth of -76.4%, EPS growth of +17.4%, a dividend yield of 0.0%. What stands out right now is revenue -76.4%, EPS +17.4%, free cash flow +11.0% with operating margin -983.7% and ROIC -55.6%. Valuation already assumes a fairly strong business story at price/sales 861.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CBLI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-76.4% vs +7.6% peer median
Operating Margin
Below sector median
-983.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2021 was reported on Aug 16, 2021, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -76.4% and EPS is at +17.4%, with operating margin around -983.7%.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CBLI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CBLI Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CBLI and SPY.
Company Overview
Cytocom, Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.